-$0.50 Earnings Per Share Expected for Heron Therapeutics, Inc. (NASDAQ:HRTX) This Quarter

Equities research analysts predict that Heron Therapeutics, Inc. (NASDAQ:HRTXGet Rating) will post ($0.50) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Heron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.36). Heron Therapeutics reported earnings of ($0.62) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 19.4%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($1.97) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.57). For the next financial year, analysts anticipate that the business will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.51) to ($1.01). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTXGet Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.18). Heron Therapeutics had a negative net margin of 258.35% and a negative return on equity of 243.85%. The business had revenue of $23.46 million during the quarter, compared to the consensus estimate of $22.61 million. During the same period in the prior year, the firm earned ($0.58) EPS. The business’s revenue for the quarter was up 17.2% on a year-over-year basis.

HRTX has been the subject of a number of recent analyst reports. Cantor Fitzgerald cut their price target on shares of Heron Therapeutics from $20.00 to $12.00 in a report on Tuesday, May 10th. Zacks Investment Research downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 9th. Cowen cut their price target on shares of Heron Therapeutics from $13.00 to $7.50 in a report on Tuesday, May 10th. Needham & Company LLC lowered their price objective on shares of Heron Therapeutics from $24.00 to $16.00 in a research report on Tuesday, March 1st. Finally, StockNews.com started coverage on shares of Heron Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating for the company.

Shares of Heron Therapeutics stock traded up $0.11 on Friday, reaching $3.29. 75,931 shares of the stock were exchanged, compared to its average volume of 2,320,433. The firm’s 50 day moving average is $4.87 and its 200-day moving average is $7.26. Heron Therapeutics has a one year low of $3.05 and a one year high of $16.63. The company has a debt-to-equity ratio of 6.22, a quick ratio of 1.79 and a current ratio of 2.39. The firm has a market cap of $337.16 million, a PE ratio of -1.43 and a beta of 1.37.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Heron Therapeutics by 1.4% during the third quarter. Geode Capital Management LLC now owns 1,612,375 shares of the biotechnology company’s stock worth $17,236,000 after buying an additional 22,983 shares during the last quarter. Balyasny Asset Management LLC increased its position in Heron Therapeutics by 22.8% during the 3rd quarter. Balyasny Asset Management LLC now owns 480,772 shares of the biotechnology company’s stock valued at $5,139,000 after purchasing an additional 89,339 shares during the period. Crestline Management LP purchased a new position in Heron Therapeutics during the 3rd quarter valued at $1,099,000. Cubist Systematic Strategies LLC grew its position in shares of Heron Therapeutics by 135.5% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 87,145 shares of the biotechnology company’s stock worth $932,000 after buying an additional 50,141 shares during the period. Finally, ArrowMark Colorado Holdings LLC boosted its stake in Heron Therapeutics by 8.8% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 6,421,335 shares of the biotechnology company’s stock worth $68,644,000 after purchasing an additional 517,367 shares in the last quarter.

About Heron Therapeutics (Get Rating)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Stories

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.